148 related articles for article (PubMed ID: 22664951)
1. Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients.
Saito S; Hayashi N; Sato N; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Watanabe M; Yoshida M; Sakai K; Katsumori T; Katahuchi S; Shigaki N; Yamada K; Kimura M; Tanigawa T; Takano S; Kuramoto M; Baba H
Int J Clin Oncol; 2013 Aug; 18(4):689-95. PubMed ID: 22664951
[TBL] [Abstract][Full Text] [Related]
2. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients.
Tamiya A; Yamazaki K; Boku N; Machida N; Kojima T; Taku K; Yasui H; Fukutomi A; Hironaka S; Onozawa Y
Int J Clin Oncol; 2009 Dec; 14(6):513-7. PubMed ID: 19967487
[TBL] [Abstract][Full Text] [Related]
3. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.
Meyerhardt JA; Li L; Sanoff HK; Carpenter W; Schrag D
J Clin Oncol; 2012 Feb; 30(6):608-15. PubMed ID: 22253466
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment.
Bai L; Zhang DS; Wu WJ; Ren C; Wang DS; Wang F; Qiu MZ; Xu RH
Med Oncol; 2015 Feb; 32(2):469. PubMed ID: 25582893
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
Hamamoto Y; Yamaguchi T; Nishina T; Yamazaki K; Ura T; Nakajima T; Goto A; Shimada K; Nakayama N; Sakamoto J; Morita S; Yamada Y
Oncologist; 2014 Nov; 19(11):1131-2. PubMed ID: 25280489
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Sato A; Koizumi W; Mizunuma N; Takiuchi H
Jpn J Clin Oncol; 2010 Oct; 40(10):913-20. PubMed ID: 20462981
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients.
De Stefano A; Carlomagno C; Pepe S; Bianco R; De Placido S
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1207-13. PubMed ID: 21409384
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.
Kiss I; Bortlicek Z; Melichar B; Poprach A; Halamkova J; Vyzula R; Dusek L; Buchler T
Anticancer Res; 2014 Feb; 34(2):949-54. PubMed ID: 24511038
[TBL] [Abstract][Full Text] [Related]
13. A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.
Nishina T; Takano Y; Denda T; Yasui H; Takeda K; Ura T; Esaki T; Okuyama Y; Kondo K; Takahashi Y; Sugiyama Y; Muro K
Jpn J Clin Oncol; 2013 Nov; 43(11):1080-6. PubMed ID: 23999770
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.
Guan ZZ; Xu JM; Luo RC; Feng FY; Wang LW; Shen L; Yu SY; Ba Y; Liang J; Wang D; Qin SK; Wang JJ; He J; Qi C; Xu RH
Chin J Cancer; 2011 Oct; 30(10):682-9. PubMed ID: 21959045
[TBL] [Abstract][Full Text] [Related]
15. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.
Österlund P; Soveri LM; Isoniemi H; Poussa T; Alanko T; Bono P
Br J Cancer; 2011 Feb; 104(4):599-604. PubMed ID: 21304526
[TBL] [Abstract][Full Text] [Related]
16. [Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer].
Horinouchi Y; Sakurada T; Nakamura T; Tajima S; Nishisako H; Abe S; Teraoka K; Kujime T; Kawazoe K; Minakuchi K
Yakugaku Zasshi; 2011; 131(8):1251-7. PubMed ID: 21804330
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry.
Slavicek L; Pavlik T; Tomasek J; Bortlicek Z; Buchler T; Melichar B; Vyzula R; Prausova J; Finek J; Majek O; Dusek L
BMC Gastroenterol; 2014 Mar; 14():53. PubMed ID: 24666582
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer.
Takii Y; Maruyama S
Chemotherapy; 2013; 59(2):79-84. PubMed ID: 23881273
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
